UB Paderborn / Katalog / Suche / in CDI

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy

Journal of medicinal chemistry, 2021-03, Vol.64 (5), p.2576-2607

2021

Volltextzugriff (PDF)

X-chromosome inactivation and epigenetic fluidity in human embryonic stem cells

Proceedings of the National Academy of Sciences - PNAS, 2008-03, Vol.105 (12), p.4820-4825

2008

Volltextzugriff (PDF)

The Phenotypic Consequences of CFTR Mutations

Annals of human genetics, 2003-09, Vol.67 (5), p.471-485

2003

Volltextzugriff (PDF)

Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates

Journal of medicinal chemistry, 2020-09, Vol.63 (17), p.9603-9622

2020

Volltextzugriff (PDF)

Higher order chromatin structure at the X-inactivation center via looping DNA

Developmental biology, 2008-07, Vol.319 (2), p.416-425

2008

Volltextzugriff (PDF)

Identification of Developmentally Specific Enhancers for Tsix in the Regulation of X Chromosome Inactivation

Molecular and Cellular Biology, 2005-04, Vol.25 (7), p.2757-2769

2005

Volltextzugriff (PDF)

CTCF mediates insulator function at the CFTR locus

Biochemical journal, 2007-12, Vol.408 (2), p.267-275

2007

Volltextzugriff (PDF)

Novel pancreatic endocrine maturation pathways identified by genomic profiling and causal reasoning

PloS one, 2013-02, Vol.8 (2), p.e56024-e56024

2013

Volltextzugriff (PDF)

Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)

Bioorganic & medicinal chemistry letters, 2020-02, Vol.30 (4), p.126907, Article 126907

2020

Volltextzugriff (PDF)

An Anti-CD22- seco -CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models

Molecular cancer therapeutics, 2021-02, Vol.20 (2), p.340-346

2021

Volltextzugriff (PDF)

Conjugation of Indoles to Antibodies through a Novel Self‐Immolating Linker

Chemistry : a European journal, 2018-04, Vol.24 (19), p.4830-4834

2018

Volltextzugriff (PDF)

Direct Tie2 Agonists Stabilize Vasculature for the Treatment of Diabetic Macular Edema

Translational vision science & technology, 2022-10, Vol.11 (10), p.27-27

2022

Volltextzugriff (PDF)

Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery

Regenerative medicine, 2010-07, Vol.5 (4), p.557-568

2010

Volltextzugriff (PDF)

Morphological restriction of human coronary artery endothelial cells substantially impacts global gene expression patterns

The FEBS journal, 2013-09, Vol.280 (18), p.4474-4494

2013

Volltextzugriff (PDF)

Gene expression analysis reveals marked differences in the transcriptome of infantile hemangioma endothelial cells compared to normal dermal microvascular endothelial cells

Vascular cell, 2013-03, Vol.5 (1), p.6-6

2013

Volltextzugriff (PDF)

An element in intron 1 of the CFTR gene augments intestinal expression in vivo

Human molecular genetics, 2001-07, Vol.10 (14), p.1455-1464

2001

Volltextzugriff (PDF)

Abstract P167: Site-specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P167-P167

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties

X-chromosome inactivation and epigenetic fluidity in human embryonic stem cells

The Phenotypic Consequences of CFTR Mutations

Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates

Higher order chromatin structure at the X-inactivation center via looping DNA

Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response

LRRC15 + myofibroblasts dictate the stromal setpoint to suppress tumour immunity

Identification of Developmentally Specific Enhancers for Tsix in the Regulation of X Chromosome Inactivation

CTCF mediates insulator function at the CFTR locus

Novel pancreatic endocrine maturation pathways identified by genomic profiling and causal reasoning

Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity

Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)

A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

An Anti-CD22- seco -CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models

Antibody–Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo

Conjugation of Indoles to Antibodies through a Novel Self‐Immolating Linker

Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody–Drug Conjugates

Direct Tie2 Agonists Stabilize Vasculature for the Treatment of Diabetic Macular Edema

Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery

Morphological restriction of human coronary artery endothelial cells substantially impacts global gene expression patterns

Gene expression analysis reveals marked differences in the transcriptome of infantile hemangioma endothelial cells compared to normal dermal microvascular endothelial cells

An element in intron 1 of the CFTR gene augments intestinal expression in vivo

Abstract P167: Site-specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

Front Cover: Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity (ChemMedChem 1/2020)

Suchergebnisse filtern